Retrometabolic drug design

Principles and recent developments

Nicholas Bodor, Peter Buchwald

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Retrometabolic drug design incorporates two major systematic approaches: the design of soft drugs (SDs) and of chemical delivery systems (CDSs). Both aim to design new, safe drugs with an improved therapeutic index by integrating structure-activity and -metabolism relationships; however, they achieve it by different means: whereas SDs are new, active therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their desired therapeutic effect, CDSs are biologically inert molecules that provide enhanced and targeted delivery of an active drug to a particular organ or site through a designed sequential metabolism that involves several steps. General principles and recent developments are briefly reviewed with various illustrative examples from different therapeutic areas with special focus on soft corticosteroids and on brain targeting.

Original languageEnglish
Pages (from-to)1669-1682
Number of pages14
JournalPure and Applied Chemistry
Volume80
Issue number8
DOIs
StatePublished - Aug 1 2008

Fingerprint

Metabolism
Pharmaceutical Preparations
Metabolites
Brain
Molecules
Adrenal Cortex Hormones

Keywords

  • Brain targeting
  • Drug design
  • Hydrolysis
  • Metabolism
  • Oxime

ASJC Scopus subject areas

  • Chemical Engineering(all)
  • Chemistry(all)

Cite this

Retrometabolic drug design : Principles and recent developments. / Bodor, Nicholas; Buchwald, Peter.

In: Pure and Applied Chemistry, Vol. 80, No. 8, 01.08.2008, p. 1669-1682.

Research output: Contribution to journalArticle

@article{f81c2694c0b84258a1e7002a808ab9f6,
title = "Retrometabolic drug design: Principles and recent developments",
abstract = "Retrometabolic drug design incorporates two major systematic approaches: the design of soft drugs (SDs) and of chemical delivery systems (CDSs). Both aim to design new, safe drugs with an improved therapeutic index by integrating structure-activity and -metabolism relationships; however, they achieve it by different means: whereas SDs are new, active therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their desired therapeutic effect, CDSs are biologically inert molecules that provide enhanced and targeted delivery of an active drug to a particular organ or site through a designed sequential metabolism that involves several steps. General principles and recent developments are briefly reviewed with various illustrative examples from different therapeutic areas with special focus on soft corticosteroids and on brain targeting.",
keywords = "Brain targeting, Drug design, Hydrolysis, Metabolism, Oxime",
author = "Nicholas Bodor and Peter Buchwald",
year = "2008",
month = "8",
day = "1",
doi = "10.1351/pac200880081669",
language = "English",
volume = "80",
pages = "1669--1682",
journal = "Pure and Applied Chemistry",
issn = "0033-4545",
publisher = "IUPAC Secretariat",
number = "8",

}

TY - JOUR

T1 - Retrometabolic drug design

T2 - Principles and recent developments

AU - Bodor, Nicholas

AU - Buchwald, Peter

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Retrometabolic drug design incorporates two major systematic approaches: the design of soft drugs (SDs) and of chemical delivery systems (CDSs). Both aim to design new, safe drugs with an improved therapeutic index by integrating structure-activity and -metabolism relationships; however, they achieve it by different means: whereas SDs are new, active therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their desired therapeutic effect, CDSs are biologically inert molecules that provide enhanced and targeted delivery of an active drug to a particular organ or site through a designed sequential metabolism that involves several steps. General principles and recent developments are briefly reviewed with various illustrative examples from different therapeutic areas with special focus on soft corticosteroids and on brain targeting.

AB - Retrometabolic drug design incorporates two major systematic approaches: the design of soft drugs (SDs) and of chemical delivery systems (CDSs). Both aim to design new, safe drugs with an improved therapeutic index by integrating structure-activity and -metabolism relationships; however, they achieve it by different means: whereas SDs are new, active therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their desired therapeutic effect, CDSs are biologically inert molecules that provide enhanced and targeted delivery of an active drug to a particular organ or site through a designed sequential metabolism that involves several steps. General principles and recent developments are briefly reviewed with various illustrative examples from different therapeutic areas with special focus on soft corticosteroids and on brain targeting.

KW - Brain targeting

KW - Drug design

KW - Hydrolysis

KW - Metabolism

KW - Oxime

UR - http://www.scopus.com/inward/record.url?scp=52449099820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52449099820&partnerID=8YFLogxK

U2 - 10.1351/pac200880081669

DO - 10.1351/pac200880081669

M3 - Article

VL - 80

SP - 1669

EP - 1682

JO - Pure and Applied Chemistry

JF - Pure and Applied Chemistry

SN - 0033-4545

IS - 8

ER -